Leishmaniasis is a vector-borne disease caused by protozoan parasites belonging to the genus Leishmania. It is transmitted by the bite of female phlebotomine sand flies. The clinical spectrum of leishmaniasis ranges from self-healing cutaneous lesions to fatal visceral disease. Leishmaniasis affects the skin, mucosal tissues of the mouth, and nose or internal organs like the spleen, liver etc. There are approximately 1.3 million new cases and over 20,000-30,000 deaths reported annually from leishmaniasis. Currently, there are limited treatment options available for leishmaniasis with high toxicity and treatment failure rates. Hence, there is a growing focus on the development of novel treatment alternatives.
The global leishmaniasis treatment market is estimated to be valued at US$ 69.4 Mn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The rising drug development activities for leishmaniasis conducted by various pharmaceutical and biotechnology companies is expected to drive the market growth over the forecast period. For instance, In September 2022, Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced a research collaboration with the Drugs for Neglected Diseases initiative (DNDi) to develop new treatment options for visceral leishmaniasis, a potentially fatal parasitic disease. Additionally, increasing investments by public and private organizations to combat neglected tropical diseases including leishmaniasis is also anticipated to boost the market.
Segment Analysis
The global leishmaniasis treatment market is segmented into cutaneous, visceral, and muco-cutaneous segments. The visceral segment currently dominates the market and accounts for nearly half of the overall market share. The high prevalence and fatal nature of visceral leishmaniasis is the primary factor driving the growth of this segment. Regional markets such as India and East Africa with high incidence of visceral leishmaniasis report a large patient pool opting for treatment options.
PEST Analysis
Political: Various governments are actively supporting efforts to control the spread of leishmaniasis through awareness programs, surveillance measures, vector control programs etc. However, lack of political stability and wars in endemic regions hamper these initiatives.
Economic: Despite being designated an NTD by WHO, financing for leishmaniasis drug development is limited due to low profit prospects in endemic regions. However, large donor funding from organizations aims to boost drug supply.
Social: Stigma around leishmaniasis affects diagnosis and treatment-seeking rates. Low health awareness in remote rural communities further exacerbates the problem.
Technological: Advances in diagnostics include development of rapid detection kits. Several vaccine candidates are under clinical trials. Orally administered therapies offer more compliance over intravenous regimens. Gene therapies hold promise for future.
Key Takeaways
The Global Leishmaniasis Treatment Market Size is expected to witness high growth during the forecast period of 2023 to 2030. The market size for 2024 is estimated to be US$ 69.4 Mn.
Regional analysis indicates South Asia and Africa as the fastest growing markets due to high disease burden.
Key players operating in the leishmaniasis treatment market are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. Market consolidation activities such as acquisitions and collaborations are common among these players to enhance product portfolios.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.